Dr. Losordo is the Chief Medical Officer and Senior Vice President of Clinical, Medical and Regulatory Affairs of Caladrius Biosciences, Inc, Adjunct Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois and Clinical Professor of Medicine at the New York University Langone Medical Center.

Dr. Losordo’s career has been dedicated to patient care and to the development of novel therapeutics aimed at the reversal or repair of chronic conditions such as heart failure, critical limb ischemia, cancer and diabetes.

A native of Brooklyn, NY, he received his medical degree from the University of Vermont. Dr. Losordo completed an internship, residency and fellowship at St. Elizabeth’s Medical, Boston, Massachusetts, where he subsequently joined the faculty, working with the late Jeff Isner to develop a program in gene therapy and cell-based tissue repair. Dr. Losordo’s group has executed the full “translational medicine” paradigm: identifying novel therapeutics in the laboratory, investigatings these strategies in small and large animal models and designing and executing first-in-human and proof-of-concept clinical trials. His work in academia included developing VEGF gene therapy for myocardial ischemia and diabetic neuropathy and CD34+ cell therapy for refractory angina, critical limb ischemia, and severe claudication. At Caladrius Dr. Losordo has initiated a phase 3 study of an immunotherapy for metastatic melanoma and a phase 2 study of autologous regulatory T cell therapy for new onset type 1 diabetes in children. In addition to his own work Dr. Losordo has also mentored numerous scientists and physician-scientists from around the world.